Literature DB >> 18986320

CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats.

Bing Cui1, Yu-Si Cheng, De-Zai Dai, Na Li, Tian-Tai Zhang, Yin Dai.   

Abstract

1. The aim of the present study was to explore the effects of CPU0213, a dual endothelin ET(A)/ET(B) receptor antagonist, and nifedipine, a calcium antagonist, in relieving pulmonary hypertension (PH). Both endothelin receptor and calcium antagonists have been reported to be effective in alleviating the remodelling of pulmonary arteries induced by monocrotaline (MCT) in rats. 2. After an initial single dose of 60 mg/kg, s.c., MCT, CPU0213 was administered to rats at doses of 25, 50 or 100 mg/kg, p.o., for 28 days. In addition, nifedipine was administered to another group of rats at a dose of 10 mg/kg, p.o., for 28 days. The haemodynamics of the right ventricle, pulmonary vascular activity, remodelling of the pulmonary arterioles (< 150 microm) and biochemical changes were evaluated. 3. Right ventricular systolic pressure (RVSP), central venous pressure (CVP), the maximum rate of uprising pressure (dP/dT(max)) and the weight index of the right ventricle were significantly elevated in MCT-treated rats. In addition, increases in pulmonary endothelin-1, malonyldialdehyde (MDA) and hydroxyproline content and a reduction in superoxide dismutase activity was found after MCT treatment. The thickness and area of the pulmonary arterial wall were significantly increased in MCT-treated rats compared with control rats. At all three doses tested, CPU0213 ameliorated these changes in a dose-dependent manner and the effects were associated with a greater reduction in the remodelling of pulmonary arterioles. However, nifedipine was only partially effective in amelerioating biochemical and haemodynamic changes induced by MCT, significantly reducing RVSP, CVP, +dp/dt(max), tissue MDA, inducible nitric oxide synthase and hydroxyproline content, increasing -dp/dt(min) and having no effect on the other parameters investigated. In addition, nifedipine had no effect on remodelling of the arterial wall. 4. In conclusion, CPU0213 is more effective than nifedipine in suppressing the remodelling of pulmonary arterioles in PH induced by MCT treatment of rats. Furthermore, CPU0213 may have promise in treating PH secondary to connective tissue disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18986320     DOI: 10.1111/j.1440-1681.2008.05044.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  8 in total

1.  The PPARγ ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo.

Authors:  Bum-Yong Kang; Jennifer M Kleinhenz; Tamara C Murphy; C Michael Hart
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-16       Impact factor: 5.464

2.  Raisanberine protected pulmonary arterial rings and cardiac myocytes of rats against hypoxia injury by suppressing NADPH oxidase and calcium influx.

Authors:  Jie Gao; Yi-qun Tang; De-zai Dai; Yu-si Cheng; Guo-lin Zhang; Can Zhang; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2012-05       Impact factor: 6.150

3.  Peroxisome Proliferator-Activated Receptor γ and microRNA 98 in Hypoxia-Induced Endothelin-1 Signaling.

Authors:  Bum-Yong Kang; Kathy K Park; Jennifer M Kleinhenz; Tamara C Murphy; David E Green; Kaiser M Bijli; Samantha M Yeligar; Kristal A Carthan; Charles D Searles; Roy L Sutliff; C Michael Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2016-01       Impact factor: 6.914

4.  Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213.

Authors:  Yu-si Cheng; De-zai Dai; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2009-07-13       Impact factor: 6.150

Review 5.  Role of endothelin receptor A and NADPH oxidase in vascular abnormalities.

Authors:  De-Zai Dai; Yin Dai
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

Review 6.  Determinants of an elevated pulmonary arterial pressure in patients with pulmonary arterial hypertension.

Authors:  Seiichiro Sakao; Norbert F Voelkel; Nobuhiro Tanabe; Koichiro Tatsumi
Journal:  Respir Res       Date:  2015-07-08

Review 7.  Current animal models for the study of congestion in heart failure: an overview.

Authors:  Jirka Cops; Sibren Haesen; Bart De Moor; Wilfried Mullens; Dominique Hansen
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

8.  Inhalation of the BK(Ca)-opener NS1619 attenuates right ventricular pressure and improves oxygenation in the rat monocrotaline model of pulmonary hypertension.

Authors:  Marc Revermann; Skevi Neofitidou; Thomas Kirschning; Manuel Schloss; Ralf P Brandes; Christian Hofstetter
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.